Loading
Gastric Cancer / Ménétrier Disease · Journal article
Den Open · August 26, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case report documents detection of early-stage, well-differentiated gastric adenocarcinoma 15 years after clinical remission of Ménétrier disease in a single patient, successfully treated by endoscopic submucosal dissection with no recurrence at the time of reporting. The observation underscores that gastric cancer risk may persist during long-term surveillance after medical remission, but the rarity of such reports and lack of population data limit any inference about incidence, risk stratification, or surveillance intensity.
Case report. Woman in her 70s with Ménétrier disease (negative H. pylori serology) in remission on steroid therapy and proton pump inhibitor; enrolled in annual esophagogastroduodenoscopy surveillance.. Intervention: Annual endoscopic surveillance; endoscopic submucosal dissection for detected gastric adenocarcinoma.. n = 1.
Type 0-I well-differentiated tubular adenocarcinoma detected 15 years after Ménétrier disease diagnosis, during annual endoscopic surveillance. Lesion was intramucosal, considered suitable for endoscopic submucosal dissection. Curative en bloc resection achieved; histopathology revealed no active Ménétrier disease.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case supports the rationale for continued endoscopic surveillance in patients with Ménétrier disease even after documented long-term clinical remission, as gastric cancer risk may not resolve. However, the incidence, optimal surveillance frequency, and outcome benefit in the broader Ménétrier disease population remain undefined and cannot be inferred from a single case.
A single case report documenting early gastric cancer detection and successful endoscopic treatment during surveillance of a patient with remote Ménétrier disease remission; raises questions about long-term cancer risk and surveillance strategy but provides no comparative data or population-level evidence.
As stated by the source record.
Quoted from the source exactly as published.
This case supports the rationale for continued endoscopic surveillance in patients with Ménétrier disease even after documented long-term clinical remission, as gastric cancer risk may not resolve. However, the incidence, optimal surveillance frequency, and outcome benefit in the broader Ménétrier disease population remain undefined and cannot be inferred from a single case.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Ménétrier disease (MD) was diagnosed based on hypoalbuminemia and giant gastric folds extending from the body to the fundus in a woman in her 70s. A serum anti-Helicobacter pylori antibody test and urea breath test yielded negative results. Remission was achieved with steroid therapy, and she was relapse-free with the use of a proton pump inhibitor. Annual esophagogastroduodenoscopy (EGD) was continued for gastric cancer surveillance. Fifteen years after the diagnosis of MD, a type 0-I well-differentiated tubular adenocarcinoma was detected on the posterior wall of the upper gastric body. EGD, computed tomography, and endoscopic ultrasonography revealed no findings suggestive of MD recurrence, and the lesion was considered intramucosal. Endoscopic submucosal dissection resulted in curative en bloc resection. Histopathology revealed no evidence of active MD. The patient remained free of MD relapse and gastric cancer recurrence. MD is characterized by giant gastric folds and protein-losing gastroenteropathy, and it is considered a risk factor for gastric cancer. However, reports of gastric cancer diagnosed at an early stage and treated endoscopically during long-term follow-up after clinical remission induced by medical therapy, as in the present case, are rare. This case highlights the importance of continued endoscopic surveillance for gastric carcinogenesis even after long-term clinical remission of MD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.